Inflammation-Based Prognostic Scores in Pancreatic Cancer Patients-A Single-Center Analysis of 1294 Patients within the Last Decade.
CRP to albumin ratio (CAR)
inflammatory benchmark index (IBI)
inflammatory biomarkers
lymphocyte to monocyte ratio (LMR)
neutrophil to lymphocyte ratio (NLR)
pancreatic cancer
platelet to lymphocyte ratio (PLR)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Apr 2023
19 Apr 2023
Historique:
received:
06
03
2023
revised:
16
04
2023
accepted:
17
04
2023
medline:
16
5
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
epublish
Résumé
Inflammatory properties are known to promote tumor progression leading to an impaired median overall survival (mOS). Various small studies have focused on a wide range of inflammation-based prognostic indicators. By using sufficient data from 1294 out of 2323 patients diagnosed with pancreatic cancer between 2009 and 2021 at our cancer center, inflammatory markers such as the neutrophil to lymphocyte ratio (NRL), the platelet to lymphocyte ratio (PLR), the lymphocyte to monocyte ratio (LMR) and the CRP to albumin ratio (CAR) were evaluated. We identified a new combined score, termed the inflammatory benchmark index (IBI). We performed univariate and multivariate overall survival analyses and identified optimal prognostic cut-off values for each parameter. In univariate analyses, advanced age (
Identifiants
pubmed: 37190296
pii: cancers15082367
doi: 10.3390/cancers15082367
pmc: PMC10136644
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Berliner Krebsgesellschaft
ID : PEFF202104
Références
Medicine (Baltimore). 2020 Jun 5;99(23):e20595
pubmed: 32502031
Intern Med J. 2014 Jul;44(7):676-82
pubmed: 24750233
World J Surg. 2016 Sep;40(9):2254-60
pubmed: 26956901
Transl Cancer Res. 2019 Feb;8(1):17-22
pubmed: 35116729
Eur J Med Res. 2020 Oct 7;25(1):46
pubmed: 33028394
Ann Surg Oncol. 2018 Dec;25(13):3996-4003
pubmed: 30225838
Asia Pac J Clin Oncol. 2022 Jun;18(3):232-239
pubmed: 34161667
Aging (Albany NY). 2020 Jan 24;12(2):1171-1185
pubmed: 31977318
Am J Pathol. 1999 Aug;155(2):537-47
pubmed: 10433946
Ann Surg Oncol. 2017 Mar;24(3):808-815
pubmed: 27770341
Endocr Connect. 2020 Apr;9(4):289-298
pubmed: 32163917
Eur J Cancer. 2020 Jun;132:71-84
pubmed: 32334338
Sci Rep. 2020 Oct 30;10(1):18758
pubmed: 33127996
Cytokine Growth Factor Rev. 2007 Feb-Apr;18(1-2):171-82
pubmed: 17329145
Curr Oncol. 2022 Dec 14;29(12):9867-9874
pubmed: 36547189
Pancreatology. 2018 Jan;18(1):2-11
pubmed: 29191513
Clin Res Hepatol Gastroenterol. 2021 May;45(3):101541
pubmed: 33055007
Cancer Manag Res. 2019 Sep 30;11:8781-8788
pubmed: 31632137
Ann Surg Oncol. 2011 Aug;18(8):2318-28
pubmed: 21267785
BMJ. 2019 Jan 30;364:k4597
pubmed: 30700442
Ann Hepatobiliary Pancreat Surg. 2018 Aug;22(3):197-207
pubmed: 30215041
BMC Cancer. 2020 Aug 11;20(1):750
pubmed: 32782024
Onco Targets Ther. 2018 Apr 05;11:1899-1908
pubmed: 29670365
Am J Clin Oncol. 2003 Apr;26(2):135-40
pubmed: 12714883
PLoS Med. 2014 Oct 14;11(10):e1001744
pubmed: 25314315
Gastroenterol Res Pract. 2018 Jun 10;2018:2373868
pubmed: 29983708
Clin Chem Lab Med. 2015 Feb;53(3):499-506
pubmed: 25389993
Pancreas. 2017 Sep;46(8):1011-1017
pubmed: 28787331
Clin Chim Acta. 2018 Jun;481:142-146
pubmed: 29544747
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Clin Chim Acta. 2018 Apr;479:181-189
pubmed: 29407690
HPB (Oxford). 2018 May;20(5):398-404
pubmed: 29221789
Int J Mol Sci. 2019 Feb 05;20(3):
pubmed: 30764482
Int J Biol Sci. 2022 Jan 1;18(1):82-95
pubmed: 34975319
Onco Targets Ther. 2016 Mar 01;9:1085-92
pubmed: 27042101
Nat Rev Clin Oncol. 2019 Jan;16(1):11-26
pubmed: 30341417